Get the Stockscreener App
0.529
3.38%
0.0173
Pre-market:
.52
-0.009
-1.70%
60 Degrees Pharmaceuticals Inc Stock (SXTP) Latest News
Pharmaceutical Funding Alert: 60 Degrees Secures Fresh Capital Through Strategic Share Offering - StockTitan
Form 424B5 60 DEGREES PHARMACEUTICA - StreetInsider.com
How does 60 Degrees Pharmaceuticals Inc (SXTP) change from a tortoise to a hare? - SETE News
60 Degrees Pharma Announces $1.075 Million Registered Direct Offering - citybiz
60 Degrees Pharma Announces $1.075 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - GlobeNewswire
Pharma Stock Alert: SXTP Secures Fresh Capital Through Strategic Share Offering at $0.715 - StockTitan
60 Degrees Pharmaceuticals Inc’s latest rating changes from various analysts - Knox Daily
Weiss Ratings Reiterates Sell (E+) Rating for 60 Degrees Pharmaceuticals (NASDAQ:SXTP) - Defense World
SXTP stock touches 52-week low at $0.7 amid market challenges - MSN
60 Degrees Pharma Announces Closing of $1.043 Million - GlobeNewswire
60 Degrees Pharma Secures Fresh Capital: Inside the $1M Financing Deal That's Turning Heads - StockTitan
60 Degrees Pharmaceuticals announces stock and warrant sale - MSN
US Stocks Mixed; General Dynamics Earnings Top Views - Benzinga
60 Degrees Pharma Announces $1.043 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - The Manila Times
Pharma Company's $1M Cash Injection Comes with Hidden UpsideComplete Analysis - StockTitan
US Futures Point To Cautious Start As Investors Await Fed's Rate Decision: Tesla, Microsoft, Meta Among Stocks In Focus Ahead Of Earnings - Benzinga
60 Degrees Pharmaceuticals obtains IRB approval for chronic babesiosis therapy trial - Yahoo! Voices
Why F5 Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket - Benzinga
60 Degrees Pharmaceuticals Gets Investigational Review Board Approval for Babesiosis Phase 2 Study - Marketscreener.com
60 Degrees Pharmaceuticals, Inc. Announces the Approval of an Investigational Review Board Commissioned Phase II Clinical Study - Marketscreener.com
60 Degrees Pharma Announces IRB Approval of Phase II Study to Evaluate Tafenoquine for Chronic Babesiosis - GlobeNewswire
Titan Pharma (NASDAQ:TTNP) Stock Quotes, Forecast and News Summary - Benzinga
Palatin Technologies Inc (AMEX: PTN) Analysts Expect It Could Climb 93.76% From Current Levels. - Stocks Register
60 Degrees Pharmaceuticals Inc (NASDAQ: SXTP) Jumps 0.32 Percent In Recent Trading, What Questions Do You Have? – Stocks Register - Stocks Register
Corn and Brent Crude calendar spread - The Globe and Mail
60 Degrees Pharmaceuticals Inc. (SXTP) Reports Q3 Loss, Misses Revenue Estimates - MSN
No Bull | The Five Spot - The Globe and Mail
Pre-market Movers: SAGE, ITCI, GCTK, MRNA... - RTTNews
60 Degrees Pharmaceuticals (NASDAQ:SXTP) Earns Neutral Rating from HC Wainwright - Defense World
Reviva Pharmaceuticals (NASDAQ:RVPH) Raised to “Strong-Buy” at Roth Capital - Defense World
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Receives $57.10 Consensus Target Price from Brokerages - Defense World
60 Degrees Pharmaceuticals Enrolls First Patient in Expanded Access Clinical Study for Babesiosis Treatment - Defense World
60 Degrees Pharmaceuticals enrolls first patient in tafenoquine study - Yahoo Finance
Barclays PLC Has $109,000 Stock Holdings in DLH Holdings Corp. (NASDAQ:DLHC) - Defense World
SXTP60 Degrees Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
60 Degrees Pharmaceuticals Enrolls First Patient in - GlobeNewswire
60 Degrees Pharma Launches Breakthrough Study for Stubborn Tick Disease Treatment After 80% Success - StockTitan
🚀 Wall Street Radar: Stocks to Watch Next Week - substack.com
Deal Watch: Regeneron Quietly Acquires UK Ophthalmology Firm Oxular - News & Insights
Wayfair Inc (W-N) QuotePress Release - The Globe and Mail
Parkinson's Treatment Advancements: Clinical Trials Begin for Potential New Therapy - Streetwise Reports
Maryland Biotech Gains Regulatory Approval - Streetwise Reports
Wainwright maintains neutral on SXTP stock after patent deal By Investing.com - Investing.com Australia
Wainwright maintains neutral on SXTP stock after patent deal - Investing.com India
60 Degrees Pharmaceuticals’ (SXTP) “Neutral” Rating Reaffirmed at HC Wainwright - Defense World
Sixty Degrees Pharmaceuticals and Tufts Medical Center - GlobeNewswire
60 Degrees Pharma Secures Exclusive Rights for Breakthrough Babesiosis Treatment with Tufts Medical Center - StockTitan
Insider Buying: Cheryl Xu Acquires 13,000 Shares of 60 Degrees P - GuruFocus.com
60 degrees pharmaceuticals director Cheryl Xu acquires $21,400 in stock - Investing.com India
60 degrees pharmaceuticals director Cheryl Xu acquires $21,400 in stock By Investing.com - Investing.com Australia
60 Degrees Pharmaceuticals (NASDAQ:SXTP) Earns “Neutral” Rating from HC Wainwright - Defense World
60 Degrees Pharma shares stay Neutral amid progress on Arakoda trial - Investing.com
60 Degrees Pharmaceuticals Expands Tafenoquine Clinical Trial for Babesiosis to Brigham and Women's Hospital - The Manila Times
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):